NFX.LSE · Nuformix plc

-

Please sign in to comment on NFX.LSE

1 Comment

Admin

3 years, 7 months ago

Nuformix plc is currently in a long term downtrend where the price is trading 21.2% below its 200 day moving average.

From a valuation standpoint, the stock is 87.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.5.

Nuformix plc's total revenue sank by 0.0% to $268K since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-66K since the same quarter in the previous year.

Finally, its free cash flow fell by 209.4% to $-162K since the same quarter in the previous year.

Based on the above factors, Nuformix plc gets an overall score of 1/5.

ISIN	GB00BYW79Y38
Industry	Biotechnology
Sector	Healthcare
CurrencyCode	GBP
Exchange	LSE

Target Price	10
PE Ratio	None
Market Cap	2M
Dividend Yield	0.0%
Beta	0.57

ABOUT

Nuformix plc

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

NFX.LSE · Nuformix plc

-

Nuformix plc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Nuformix plc using a moving average strategy